The gist: This story describes the results of a clinical trial with volunteer patients to test an ovarian cancer treatment that combines the new drug trebananib with standard paclitaxel chemotherapy. The study focused specifically on women with recurrent epithelial ovarian cancer who had three or fewer previous treatments and had experienced no worsening of their disease (“platinum-free interval”) in 12 months or less. The researchers found that patients who took the trebananib plus paclitaxel treatment lived longer without their cancer worsening than patients who only took paclitaxel. However, trebananib seemed to increase the risk for edema as a side effect.
“The addition of trebananib to weekly paclitaxel significantly extended PFS in women with recurrent epithelial ovarian cancer, according to results of a double blind, placebo-controlled phase 3 trial.
“Researchers observed increased incidence of edema with trebananib (AMG 386, Amgen) compared with placebo, but differences in other adverse events typically associated with anti-vascular endothelial growth factor agents were minimal between the two study arms.
“ ‘The results from the TRINOVA-1 study are clinically significant because they validate both a new target and a new therapeutic agent in the setting of epithelial ovarian cancer,’ Bradley J. Monk, MD, of Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center, and colleagues wrote. ‘Trebananib plus paclitaxel might provide a non-vascular endothelial growth factor anti-angiogenesis treatment option to women with recurrent epithelial ovarian cancer, if approved by regulatory agencies.’ ”